Hang Onto The Launch: Investor Outlook Is Brighter For Some Biotechs
Executive Summary
Successful biotech launches like Regeneron’s Eylea, Vertex’s Incivek and others have investors reconsidering the “short the launch” mentality that pervaded the industry a year ago, though no one is throwing caution to the wind.